Actin-related protein 2/3 complex subunit 2 (ARPC2) is one of the evolutionarily conserved subunits of actin-related protein 2/3 complex (Arp2/3).
In this article, we determined that ARPC2 promotes both proliferation and invasion in the human gastric cancer cell line MKN-28 by using a cell total number assay, MTT assay, cell colony formation assay, migration assay, invasion assay, and wound healing assay.
Western blot analysis was carried out to test the protein level of ARPC2, which was performed as described previously .
In this study, we tested the protein level of ARPC2. The stained sections were reviewed and scored using an Olympus microscope (Olympus America Inc., Melville, NY).
Association of ARPC2 Expression with Clinic-Pathological Features from Patients with Gastric Cancer.
Karlsen et al., "Sequence variants in IL10, ARPC2
and multiple other loci contribute to ulcerative colitis susceptibility," Nature Genetics, vol.
PA inhibited the expressions of ARPC2 and CTNND1 that are associated with the formation of actin cytoskeleton, focal adhesion and cellular protrusions.
The primary antibodies against CDK 4, cyclin D1, p21/Cip, mTOR, phospho-mTOR (Ser2448), phospho-4EBP1 (Ser65), S6 Ribosomal Protein, phospho-S6 Ribosomal Protein (Ser235/236) were purchased from Cell Signaling Technology (Beverly, MA); [beta]-actin and 4E-BP1 were obtained from Sigma; ARPC2 was purchased from Abeam (Burlingame, CA); GRB-2 was purchased from BD Biosciences (Bedford, MA).
PA also down-regulated pl20-catenin (CTNND1), actin-related protein 2/3 complex subunit 2 (ARPC2) and stathmin (STMN1).
The protein expressions of CDK 4 (cellular growth and proliferation), ARPC2 (cellular assembly and organization) and GRB-2 (cell-to-cell signaling) detected from western blot analyses corroborated to their respective iTRAQ ratios (Fig.
ARPC2, a core subunit of the Arp2/3 actin nudeator, associated with formation of actin filaments and cellular protrusion was found to be down-regulated in response to treatment of PA at 7.0 [micro]M.
This set of 5 markers (ARPC2
, FN1, RGS1, SPP1, and WNT2) was selected on the basis of the following criteria: (1) the markers were discovered to be differentially expressed in a few fresh frozen primary melanomas (13) and (2) commercially available antibodies were available for testing.